<DOC>
	<DOCNO>NCT03006705</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety postoperative adjuvant chemotherapy ONO-4538 combination tegafur-gimeracil-oteracil potassium ( S-1 therapy ) capecitabine + oxaliplatin ( CapeOX therapy ) , comparison placebo combination S-1 therapy CapeOX therapy , pStage III gastric cancer ( include esophagogastric junction cancer ) D2 extensive lymph node dissection .</brief_summary>
	<brief_title>Study Adjuvant ONO-4538 With Resected Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients histologically confirm adenocarcinoma stomach Patients without remnant cancer ( R0 ) undergone gastrectomy Gastric carcinoma accord stage classification AJCC/UICC TNM Classification , 7th Edition basis overall postoperative finding Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) score 0 1 Patients receive nonsurgical treatment ( e.g. , radiotherapy , chemotherapy , hormone therapy ) gastric cancer Multiple primary cancer A current past history severe hypersensitivity antibody product Any concurrent autoimmune disease past history chronic recurrent autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ONO-4538 , BMS-936558 , Nivolumab , gastric , adjuvant , S-1 , CapeOX</keyword>
</DOC>